drugset / Trial / NCT01331928
Sequential Chemotherapy With Xelox Follows by TX to Treat Gastric Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether sequential chemotherapy with capecitabine plus oxaliplatin (Xelox) followed by docetaxel plus capecitabine (TX)in unresectable gastric cancer.
Timeline
- Start
- 2011-01
- Primary completion
- 2013-01
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 825 mg/m2 | Oral |
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Subject | Docetaxel | Small molecule | 30 mg/m2 | Intravenous |
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | Intravenous |